Ellen G Engelhardt
Overview
Explore the profile of Ellen G Engelhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Terra L, Beekman M, Engelhardt E, Heemskerk-Gerritsen B, van Beurden M, Roeters van Lennep J, et al.
Am J Obstet Gynecol
. 2022 Nov;
228(4):440.e1-440.e20.
PMID: 36403862
Background: Women with a BRCA1/2 pathogenic variant are advised to undergo premenopausal risk-reducing salpingo-oophorectomy after completion of childbearing, to reduce their risk of ovarian cancer. Several studies reported less sexual...
12.
Schmitz R, Wilthagen E, Van Duijnhoven F, van Oirsouw M, Verschuur E, Lynch T, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35805030
Even though Ductal Carcinoma in Situ (DCIS) can potentially be an invasive breast cancer (IBC) precursor, most DCIS lesions never will progress to IBC if left untreated. Because we cannot...
13.
Bokkers K, Vlaming M, Engelhardt E, Zweemer R, van Oort I, Kiemeney L, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205807
Background: Non-genetic healthcare professionals can provide pre-test counseling and order germline genetic tests themselves, which is called mainstream genetic testing. In this systematic review, we determined whether mainstream genetic testing...
14.
Custers P, Geubels B, Huibregtse I, Peters F, Engelhardt E, Beets G, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944953
Total mesorectal excision for rectal cancer is a major operation associated with morbidity and mortality. For older or inoperable patients, alternatives are necessary. This prospective study evaluated the oncological and...
15.
Byng D, Retel V, Engelhardt E, Groothuis-Oudshoorn C, van Til J, Schmitz R, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439126
As ongoing trials study the safety of an active surveillance strategy for low-risk ductal carcinoma in situ (DCIS), there is a need to explain why particular choices regarding treatment strategies...
16.
Alaeikhanehshir S, Engelhardt E, van Duijnhoven F, van Seijen M, Bhairosing P, Pinto D, et al.
Breast
. 2020 Mar;
50:95-103.
PMID: 32120064
Objective: The majority of 'low-risk' (grade I/II) Ductal Carcinoma In Situ (DCIS) may not progress to invasive breast cancer during a women's lifetime. Therefore, the safety of active surveillance versus...
17.
Engelhardt E, Smets E, Sorial I, Stiggelbout A, Pieterse A, Hillen M
Med Decis Making
. 2019 Dec;
40(1):52-61.
PMID: 31789100
. Adjuvant systemic treatment for early stage breast cancer significantly reduces the risk of mortality but is associated with side effects, reducing patients' quality of life. Decisions about adjuvant treatment...
18.
Klaver K, Duijts S, Engelhardt E, Geusgens C, Aarts M, Ponds R, et al.
J Cancer Surviv
. 2019 Nov;
14(2):168-178.
PMID: 31768861
Purpose: Cancer-related cognitive problems (cancer-related cognitive problems) in working cancer survivors are found to affect work outcomes. We aimed to generate in-depth information regarding cancer-related cognitive problems in working cancer...
19.
Revesz D, Engelhardt E, Tamminga J, Schramel F, Onwuteaka-Philipsen B, van de Garde E, et al.
J Cancer Educ
. 2019 Jan;
35(2):345-351.
PMID: 30685832
Treatment decision-making for patients with incurable non-small cell lung cancer (NSCLC) is complex due to the rapidly increasing number of treatments and discovery of new biomarkers. Decision support systems (DSS)...
20.
Engelhardt E, Revesz D, Tamminga H, Punt C, Koopman M, Onwuteaka-Philipsen B, et al.
BMC Med Inform Decis Mak
. 2018 Dec;
18(1):132.
PMID: 30551735
Background: Decision-making about palliative care for metastatic colorectal cancer (mCRC) consists of many different treatment-related decisions, and there generally is no best treatment option. Decision support systems (DSS), e.g., prognostic...